Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CVN424 is a selective and novel GPR6 Inverse agonist effective in models of Parkinson Disease.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 22,500 | |||
5 mg | 在庫あり | ¥ 58,500 | |||
10 mg | 在庫あり | ¥ 91,000 | |||
25 mg | 在庫あり | ¥ 152,500 | |||
50 mg | 在庫あり | ¥ 217,000 | |||
100 mg | 在庫あり | ¥ 294,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 61,000 |
説明 | CVN424 is a selective and novel GPR6 Inverse agonist effective in models of Parkinson Disease. |
In vivo | CVN424 is brain-penetrant and shows dose-dependent receptor occupancy that attained brain 50% of receptor occupancy at plasma concentrations of 6.0 and 7.4 ng/ml in mice and rats, respectively[1]. |
分子量 | 473.52 |
分子式 | C24H29F2N5O3 |
CAS No. | 2254706-21-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60mg/mL (126.71 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CVN424 2254706-21-1 Endocrinology/Hormones GPCR/G Protein GPR penetrant GPR6 inhibit orally brain Inhibitor CVN 424 Parkinson disease CVN-424 inhibitor